Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RBC transfusion Clear all
Completed No phase listed Observational

RBC Irradiation, Anemia and Gut Injury

NCT02741648
View directory record Official record
Conditions
Anemia, Necrotizing Enterocolitis
Interventions
Near Infrared Spectroscopy, Non-invasive Image-based Anemia Assessment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 5 Days
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 5, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

NCT02684747
View directory record Official record
Conditions
Blood Transfusion, Autologous, Blood Doping
Interventions
Autologous Transfusion, Control - Normal Saline (Placebo)
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Red Blood Cell (RBC) Survival Following Transfusion in Infants

NCT00731588
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III
Biological
Lead sponsor
John A Widness
Other
Eligibility
1 Hour to 6 Months
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 5, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

NCT01222195
View directory record Official record
Conditions
Leukemia
Interventions
Lenalidomide, Darbepoetin alfa
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

SMaRT Blood: Single-unit Versus Multiple-unit Packed Red Blood Cell Transfusion in Non-acute Postpartum Anemia

NCT03419780
View directory record Official record
Conditions
Postpartum Anemia Nos
Interventions
Blood Transfusion
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

Optimized Erythropoietin (EPO) Treatment

NCT02075970
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Epoetin Alpha
Drug
Lead sponsor
University of Iowa
Other
Eligibility
Up to 2 Days
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

NCT03194542
View directory record Official record
Conditions
Primary Myelofibrosis, Anemia
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Stanford, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Not applicable Interventional

Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients

NCT00751322
View directory record Official record
Conditions
Pulmonary Edemas, Blood Protein Disorders
Interventions
RBC transfusion of 5 days or less storage age, RBC transfusion of conventional storage age
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2012 · Synced Sep 5, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

NCT00840827
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
lenalidomide, cyclosporine A
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 5, 2026, 1:16 PM EDT
Withdrawn Phase 2 Interventional

Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion

NCT02217683
View directory record Official record
Conditions
Hypertension, Pulmonary, Hemolysis
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Sep 5, 2026, 1:16 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

NCT03999229
View directory record Official record
Conditions
Transfusion Related Complication
Interventions
SNO, Normal Saline, Red Blood Cell
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 35 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery

NCT00651573
View directory record Official record
Conditions
Anemia
Interventions
Blood transfusion at hematocrit value less than 24%, Blood transfusion at hematocrit value less than 28%
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 5, 2026, 1:16 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

NCT03682536
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin alfa
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
25
States / cities
Berkeley, California • San Diego, California • Whittier, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 5, 2026, 1:16 PM EDT
Active, not recruiting Phase 3 Interventional

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

NCT04084080
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Red Blood Cell, Standard of care
Biological · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
20
States / cities
Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 5, 2026, 1:16 PM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

NCT02943668
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndrome
Interventions
Deferasirox, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Not applicable Interventional Results available

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

NCT00951808
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Single blood transfusion, Standard care
Biological · Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Sep 5, 2026, 1:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Blood Warming in Preterm Infants to Decrease Hypothermia

NCT05170633
View directory record Official record
Conditions
Preterm Birth, Blood Transfusion Complication, Hypothermia
Interventions
Ranger blood warmer (3M Healthcare, Oakdale, Minnesota)
Device
Lead sponsor
University of South Carolina
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 5, 2026, 1:16 PM EDT
Completed No phase listed Observational

Long Term Effects of Erythrocyte Lysis

NCT00842621
View directory record Official record
Conditions
Sickle Cell Disease, Hemolytic Anemia
Interventions
Clinical Evaluations, Laboratory Studies
Procedure · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Sep 5, 2026, 1:16 PM EDT
Completed Phase 3 Interventional Results available

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes
Interventions
Erythropoietin, Filgrastim, Transfusion
Biological · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
28
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 5, 2026, 1:16 PM EDT
Completed No phase listed Observational

Clinical Impact of Red Cell Storage Age

NCT05482737
View directory record Official record
Conditions
RBC Transfusions
Interventions
no intervention
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
33,000 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 5, 2026, 1:16 PM EDT
Not yet recruiting Not applicable Interventional

Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations

NCT07598357
View directory record Official record
Conditions
Pancreatic Surgery
Interventions
The Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 5, 2026, 1:16 PM EDT